Bonness Enterprises’s GSK GSK Stock Holding History

Bonness Enterprises’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Hold	41,480	–	–	0.7%	28
2026 Q1	$2.29M	Hold	41,480	–	–	0.84%	25
2025 Q4	$2.03M	Hold	41,480	–	–	0.7%	27
2025 Q3	$1.79M	Hold	41,480	–	–	0.59%	29
2025 Q2	$1.59M	Hold	41,480	–	–	0.52%	31
2025 Q1	$1.61M	Hold	41,480	–	–	0.52%	29
2024 Q4	$1.4M	Sell	41,480 -11,480	-22%	-$413K	0.49%	32
2024 Q3	$2.17M	Hold	52,960	–	–	0.72%	26
2024 Q2	$2.04M	Hold	52,960	–	–	0.75%	25
2024 Q1	$2.27M	Hold	52,960	–	–	0.82%	23
2023 Q4	$1.96M	Hold	52,960	–	–	0.82%	25
2023 Q3	$1.92M	Hold	52,960	–	–	0.88%	24
2023 Q2	$1.89M	Hold	52,960	–	–	0.85%	25
2023 Q1	$1.88M	Hold	52,960	–	–	0.84%	25
2022 Q4	$1.86M	Hold	52,960	–	–	0.88%	27
2022 Q3	$1.56M	Hold	52,960	–	–	0.83%	29
2022 Q2	$2.88M	Hold	52,960	–	–	1.44%	18
2022 Q1	$2.88M	Hold	52,960	–	–	1.33%	21
2021 Q4	$2.92M	Buy	52,960 +1,600	+3%	+$83.2K	1.35%	21
2021 Q3	$2.45M	Hold	51,360	–	–	1.25%	23
2021 Q2	$2.56M	Buy	51,360 +25,120	+96%	+$1.21M	1.29%	24
2021 Q1	$1.17M	Buy	26,240 +480	+2%	+$21.8K	0.63%	34
2020 Q4	$1.19M	Buy	25,760 +1,840	+8%	+$84.5K	0.66%	32
2020 Q3	$1.13M	Hold	23,920	–	–	0.66%	32
2020 Q2	$1.22M	Hold	23,920	–	–	0.78%	31
2020 Q1	$1.13M	Hold	23,920	–	–	0.82%	30
2019 Q4	$1.41M	Hold	23,920	–	–	0.88%	31
2019 Q3	$1.28M	Hold	23,920	–	–	0.82%	32
2019 Q2	$1.2M	Hold	23,920	–	–	0.75%	34
2019 Q1	$1.25M	Buy	23,920 +160	+0.7%	+$8K	0.81%	34
2018 Q4	$1.14M	Hold	23,760	–	–	0.85%	34
2018 Q3	$1.19M	Hold	23,760	–	–	0.78%	36
2018 Q2	$1.2M	Hold	23,760	–	–	0.85%	35
2018 Q1	$1.16M	Hold	23,760	–	–	0.81%	39
2017 Q4	$1.05M	Sell	23,760 -9,600	-29%	-$443K	0.71%	41
2017 Q3	$1.69M	Buy	33,360 +14,320	+75%	+$726K	1.21%	32
2017 Q2	$1.03M	Hold	19,040	–	–	0.78%	41
2017 Q1	$1M	Hold	19,040	–	–	0.8%	42
2016 Q4	$917K	Sell	19,040 -2,320	-11%	-$115K	0.82%	37
2016 Q3	$1.15M	Buy	21,360 +160	+0.8%	+$8.77K	0.96%	37
2016 Q2	$1.15M	Hold	21,200	–	–	0.97%	36
2016 Q1	$1.07M	Hold	21,200	–	–	0.92%	37
2015 Q4	$1.07M	Buy	21,200 +800	+4%	+$40.8K	0.96%	37
2015 Q3	$980K	Buy	20,400 +2,400	+13%	+$125K	0.93%	39
2015 Q2	$937K	Buy	18,000 +640	+4%	+$36K	0.84%	39
2015 Q1	$1M	Hold	17,360	–	–	0.89%	39
2014 Q4	$927K	Hold	17,360	–	–	0.8%	41
2014 Q3	$998K	Hold	17,360	–	–	0.9%	40
2014 Q2	$1.16M	Sell	17,360 -1,600	-8%	-$108K	1.05%	39
2014 Q1	$1.27M	Hold	18,960	–	–	1.11%	35
2013 Q4	$1.26M	Hold	18,960	–	–	1.12%	33
2013 Q3	$1.19M	Hold	18,960	–	–	1.14%	31
2013 Q2	$1.18M	Buy	+18,960	New	+$1.2M	1.17%	31

Other funds holding GSK

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

MHI

Miller Howard Investments Kingston, New York $3.77B AUM 23.82% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Bonness Enterprises's GSK Position: Q2 2026 in Review

Bonness Enterprises held its GSK (GSK) position steady in Q2 2026 at 41,480 shares worth $2.17M. The position accounts for 0.7% of the portfolio, ranked #28.

Bonness Enterprises first reported a position in GSK in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.92M in Q4 2021. 455 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bonness Enterprises held 41,480 shares of GSK worth $2.17M as of Q2 2026.
Bonness Enterprises left its GSK share count unchanged in Q2 2026.
GSK made up 0.7% of Bonness Enterprises's portfolio in Q2 2026, its #28 holding.
Bonness Enterprises first reported a position in GSK in Q2 2013 and has held it in 53 quarters since.
Bonness Enterprises's GSK position peaked at $2.92M in Q4 2021.
455 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bonness Enterprises's 13F filing for Q2 2026, filed 9 Jul 2026.